Number of Employees: Approximately 700
Welcome to Philip Morris Australia. Established in 1954 and based in Melbourne, we were the first affiliate in the world to produce Philip Morris International brands outside of the United States. Today we manufacture many leading tobacco brands in our factory in Moorabbin, where we also produce products for New Zealand. We employ approximately 700 employees in Australia, including around 170 people in our Moorabbin factory.
We are committed to protecting the environment where we operate and have made substantial progress in reducing our environmental footprint. Since 2004 we have successfully reduced our water usage by over 70%. Our factory improvements also helped us reduce our energy use by approximately 70% since 2004. PML is also a signatory to the Australian Packaging Covenant (APC), a voluntary program to reduce the environmental impact of packaging. Since 2004 PML has reduced its factory waste generation by more than 60%. A copy of PML’s APC Action Plan is available here, while you can view the company’s APC Annual Report here.
Smoking and Health
Tobacco products, including cigarettes, are dangerous and addictive. There is overwhelming medical and scientific evidence that smoking causes lung cancer, heart disease, emphysema, and other serious diseases.
All tobacco products are addictive. It can be very difficult to quit smoking, but this should not deter smokers who want to quit from trying to do so.
Public health officials have concluded that secondhand smoke from cigarettes causes serious diseases in non-smokers, including lung cancer and heart disease. We believe the public health conclusions on secondhand smoke are sufficient to support smoking restrictions in public places.
Philip Morris International (PMI) supports comprehensive regulation of tobacco products based on the principle of harm reduction.
To be effective, tobacco regulatory policy must be evidence-based, apply to all tobacco products, and should take into account the views of all legitimate stakeholders including public health authorities, government finance authorities, tobacco manufacturers, and other members of the tobacco supply chain. Regulatory policy must consider the potential to trigger adverse consequences which undermine public health objectives, such as increasing the demand for illicit cigarettes.
While we support comprehensive, effective tobacco regulation, we do not support regulation that prevents adults from buying and using tobacco products or that imposes unnecessary impediments to the operation of the legitimate tobacco market. In that regard, we oppose measures such as generic packaging, point of sale display bans, total bans on communications to adult consumers, and bans on the use of all ingredients in tobacco products.